A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations
Advanced Solid Tumors With HER2 Mutation,eg:Colorectal,Urothelial,Gastric, Hepatobiliary,Endometrial,Melanoma,Ovarian,Cervical,Salivary Gland,Pancreatic,Breast
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 102 (final count)
- Started
- Dec 30, 2020
- Main results expected
- Jan 25, 2023
- Fully finished
- Jul 14, 2026
- Results posted
- Feb 15, 2024
What counts as success
The trial's main goal(s), called the “primary outcome.”
Confirmed Overall Response Rate (ORR) as Per RECIST v1.1 Using Independent Central Review (ICR)
Measured over: Tumor scans performed at screening,then every 6 weeks (q6w) +/- 1 week relative to date of first treatment administration until RECIST v1.1 objective PD, withdrawal of consent, or death by any cause, up to DCO date of 25 Jan 2023 (approximately 24 months)
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT04639219 · record last updated 2026-03-23 · checked 2026-11-09 15:47 UTC